Review Article

Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward

Table 1

Trials of curative strategy for gastric cancer.

TrialPatients numberInterventionOSDFS

INT-0116A: 275
B: 281
A: Surgery
B: Surgery→CRT
HR = 1.32; HR = 1.51;

CALGB-80101A: 272
B: 274
A: Surgery→CRT
B: Surgery→ECF/CRT/ECF
HR = 1.03; HR = 1;

ARTISTA: 228
B: 230
A: Surgery→XP
B: Surgery→XP/CRT/XP
NRHR = 0.687;

MAGICA: 253
B: 250
A: Surgery
B: ECF→Surgery→ECF
HR = 0.75; HR = 0.66;

ACTS-GCA: 530
B: 529
A: Surgery
B: Surgery→S-1
HR = 0.68; HR = 0.62;

CLASSICA: 515
B: 520
A: Surgery
B: Surgery→CAPOX
HR = 0.72; HR = 0.75;

SAMITA: 359
B: 364
C: 355
D: 355
A: Surgery→UFT
B: Surgery→S-1
C: Surgery→Pac/UFT
D: Surgery→Pac/S-1
NR(i) C + D versus A + B,
HR = 0.92;
(ii) A + C versus B + D,
HR = 1.23; NR

CRT: chemoradiation.
ECF: epirubicin/cisplatin/5-fluorouracil.
NR: not reported.
XP: cisplatin/capecitabine.
CAPOX: oxaliplatin/capecitabine.